ACRUX LIMITED — Board/Management Information 2013

Oct 1, 2013

ACRUX (ACR) - ASX ANNOUNCEMENT

2 OCTOBER 2013

NEW DIRECTOR APPOINTED AT ACRUX

Acrux (ASX: ACR) today announced that Dr Tim Oldham has joined the board as a non-executive director.

Tim brings to the board more than a decade of business development, alliance management and sales and marketing experience in Europe, Asia and Australia acquired in senior management roles with Mayne Pharma and most recently as President Asia Pacific for Hospira. These roles encompassed the development and commercialisation of pharmaceuticals, devices and biologics. Prior to this, Tim qualified as a solicitor and obtained a PhD in Chemistry from Imperial College in London before embarking on a successful career with McKinsey and Co.

Acrux Chairman Ross Dobinson commented “We are very pleased to announce the appointment of Tim Oldham to the Acrux Board. Tim is highly respected within the pharmaceutical sector, and he has industry-specific strategic and commercialisation skills, which complement the skill and experience bases of the existing Board members. His appointment reflects the continuing evolution of Acrux as the company develops into one of Australia’s leading pharmaceutical companies.

Contact

Ross Dobinson, Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• The Acrux technology, used in marketed products including AXIRON®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drugs through the skin for long acting delivery.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==

• Acrux has three products marketed by licensees in the USA, two products approved in Europe, one product in registration in Europe and further products at earlier stages of development.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==